Anti-p53 TCR-Gene
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes (NCT00393029) | National Cancer Institute (NCI) | 2006-10-01 |
Track Anti-p53 TCR-Gene automatically
Every clearance here is in the API, with alerts when new ones post.